ZYMEZymeworks Inc.
Price
+59%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth fading, the market undecided.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Zymeworks Inc. (ZYME) reported revenue of $4.6M in Q2 2026 (quarter ended Jun 30, 2026), down 91% from the same quarter a year earlier. That came with net loss of $45M. For the full year FY2025, revenue was $106M (+39% year on year) and net income −$81M. Its largest product in Q2 2026 was Royalty at $1.6M, 59% of the disclosed total, well ahead of Drug Supply For Ongoing Studies at 29%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026Contingent Value Rights Agreement On September 22, 2026, in connection with the consummation of the Merger and in accordance with the Merger Agreement, Zymeworks, Computershare Inc. (“Computershare”) and Computershare Trust Company, N.A., acting jointly with Computershare, as rights agent (the “Rights Agent”), entered …Material agreement entered · Form 8-K
- Aug 25, 2026REGULATION FD DISCLOSURES Zymeworks BC Inc. (“Zymeworks”), a subsidiary of the Company, is a party to an Amended and Restated License and Collaboration Agreement (as amended, the “License and Collaboration Agreement”) with Jazz Pharmaceuticals Ireland Limited, a subsidiary of Jazz Pharmaceuticals plc, collectively …Regulation FD disclosure · Form 8-K
- Aug 6, 2026Zymeworks Provides Corporate Update and.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $2.7MThe company’s own SEC segment disclosure.
- Royalty$1.6M59%
- Drug Supply For Ongoing Studies$791.0K29%
- Research Support Payments And Other Service$291.0K11%
- Drug Supply$45.0K2%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.